1d
MedPage Today on MSNOnce-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly DosingA once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Health and Me on MSN3h
Yearly Jab For HIV Protection Is Now Almost HereA yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
1d
LGBTQ Nation on MSNOnce-a-year shot for HIV protection passes early safety trialAn annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...
Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the ...
2d
Queerty on MSNA once-a-year PrEP injection? The results of the first clinical trial look promisingPharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results